Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex Inc. (ZYXI) is a leader in non-invasive medical technology, specializing in electrotherapy devices, pain management solutions, and advanced patient monitoring systems. This news hub provides investors and industry professionals with essential updates on the company’s latest developments, regulatory milestones, and strategic initiatives.
Access real-time information on Zynex’s FDA clearances, product innovations, and financial performance. Our curated news collection covers earnings reports, partnership announcements, clinical trial outcomes, and market expansion efforts. Stay informed about developments across Zynex Medical’s therapeutic devices, Monitoring Solutions’ cardiac technologies, and Neurodiagnostics’ advancements in neurological care.
This resource is designed for those tracking Zynex’s progress in bringing clinically validated medical devices to market. Discover updates on key focus areas including TENS therapy improvements, laser-based monitoring innovations, and compliance with global medical standards. Bookmark this page for streamlined access to press releases, analyst insights, and objective reporting on Zynex’s role in shaping healthcare technology.
Zynex, a medical technology company listed under Nasdaq: ZYXI, has announced it will report its first-quarter financial results for 2023 on April 27, 2023. The report will include insights into their non-invasive medical devices for pain management and rehabilitation. Management will discuss the results during a conference call and webcast scheduled for 2:15 PM MT / 4:15 PM ET. Interested participants can register via the provided link or dial in.
Founded in 1996, Zynex specializes in developing and selling medical devices used in hospitals and patient care. The company emphasizes its forward-looking statements regarding future conditions and the inherent uncertainties involved.
Zynex, Inc. (NASDAQ: ZYXI) reported preliminary results for Q1 2023, showcasing significant growth in the pain management division. Orders reached a record high, up 61% from Q1 2022. Revenue estimates for the quarter are projected between $39.0 million and $41.0 million, reflecting a 29% increase from the previous year. The company maintains its full-year guidance, forecasting revenue of $180 million to $200 million and earnings per share between $0.40 and $0.50. Seasonal trends in the healthcare industry affect Q1 revenues, aligning with historical patterns. CEO Thomas Sandgaard emphasized strong sales momentum and growth potential as the company expands its market presence.
Zynex, Inc. (NASDAQ: ZYXI) has been ranked 191 out of 500 on The Financial Times' fourth annual list of The Americas' Fastest Growing Companies 2023. This recognition highlights Zynex's consistent revenue growth, achieving a remarkable 308% increase in revenue and a compound annual growth rate (CAGR) of 60% between 2018 and 2021. CEO Thomas Sandgaard emphasized that this accolade reflects the company's ongoing performance along with 24 other publicly traded companies in the Healthcare & Life Sciences sector. Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
Zynex, Inc. (Nasdaq: ZYXI) reported strong financial results for Q4 and full year 2022, highlighting a 21% revenue growth year-over-year to $48.8 million for Q4, with orders up 48%. Full year revenue also increased 21%, totaling $158.2 million, while net income reached $17.0 million, reflecting profitability for the seventh consecutive year. The company's working capital stood at $48.5 million, with cash on hand at $20.1 million. For 2023, Zynex projects revenue between $180 million and $200 million, anticipating first quarter revenue of $39-41 million, influenced by seasonal trends.
Zynex, Inc. (NASDAQ: ZYXI) announced the rescheduled release date for its fourth quarter and full-year 2022 financial results, now set for March 13, 2023. The company specializes in non-invasive medical devices for pain management and rehabilitation. A conference call will occur at 6:30 a.m. MT / 8:30 a.m. ET to discuss these results and provide a corporate update. Zynex has a longstanding commitment to innovation in medical technology and is focused on delivering advanced solutions for patient care.
Zynex, Inc. (NASDAQ: ZYXI) announced the postponement of its fourth quarter and full year 2022 financial results and conference call originally scheduled for March 6, 2023. The company aims to allow more time for year-end closing procedures. The specific date for the rescheduled announcement will be provided in a future press release.
Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring. Founded in 1996, the company continues to innovate in the medical technology sector.
Zynex, Inc. (NASDAQ: ZYXI) announced it will report its fourth quarter and full-year 2022 financial results on March 6, 2023. The event will include a conference call at 2:15 p.m. MT / 4:15 p.m. ET to discuss financial outcomes and provide a corporate update. Zynex specializes in non-invasive medical devices for pain management and rehabilitation. Investors may participate by registering through the provided links or dialing in. Key factors influencing Zynex's performance include their dependence on insurance reimbursements, product acceptance in the medical community, and competition from larger firms.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
